

# S2433 Kickoff

## Phase 3 Study in Pancreatic Cancer

FRIDAY, MAY 1 • 12:45 – 1:45 PM PT • GARDEN ROOM (ATRIUM LEVEL) & ONLINE

S2433: A randomized phase 3 study of second-line chemotherapy with or without panitumumab in *KRAS* wild type, locally advanced or metastatic pancreatic adenocarcinoma

S2433 asks if adding the EGFR inhibitor panitumumab to physician's choice of second-line standard-of-care chemotherapy can extend overall survival in these patients.

S2433 includes patient-reported outcomes (PRO) comparing measures of health-related quality of life and the impact of treatment toxicity.

The kickoff will offer information and practical guidance on



S2433  
background  
and objectives



key eligibility  
and treatment  
details



study chair  
review of  
genomic profiles



study drug  
ordering



PRO and  
specimen  
collection

S2433 activated in December 2025, with an enrollment goal of 94 patients.

## Attend the S2433 Kickoff

Bring your questions for a Q&A with the study team.

**All NCTN and NCORP investigators and staff are invited.**

Hybrid session: IN-PERSON & VIRTUAL attendance options

### STUDY CHAIR



Rachael  
Safyan, MD

### CO-CHAIR



E. Gabriel  
Chiorean, MD

### OTHER PRESENTERS AND PANELISTS WILL INCLUDE

*Sarah Colby, MS – Statistician*

*Andrea Garcia – Protocol Project Manager*

*Harshabad Singh, MBBS, MD – TM Co-Chair*

*Virginia Sun, PhD, MSN, RN – PRO Co-Chair*

*Brian Zeller – Data Coordinator*